Consumer Staples: Risks From Anti-Obesity Medications Likely Overblown

Anti-obesity medications (AOMs), including glucagon-like peptide-1 (GLP-1) agonists, have recently seen a substantial increase in popularity. Initially developed for type 2 diabetes management due to their ability to regulate blood sugar levels, these medications have found a new application in weight management. They work by slowing down the movement of food through the stomach, which helps individuals feel fuller sooner and for a longer duration.